SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SCHOTT Pharma AG & Co KgaA (1SXP)
SCHOTT Pharma AG & Co KgaA stock price live, this page displays ETR 1SXP stock exchange data. View the 1SXP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the SCHOTT Pharma AG & Co KgaA real time stock price chart below.
What Is the SCHOTT Pharma AG & Co KgaA Stock Price Today?
The SCHOTT Pharma AG & Co KgaA stock price today is 14.98.
What Is the Stock Symbol for SCHOTT Pharma AG & Co KgaA?
The stock symbol for SCHOTT Pharma AG & Co KgaA is "1SXP."
What Stock Exchange Does SCHOTT Pharma AG & Co KgaA Trade On?
SCHOTT Pharma AG & Co KgaA is listed and trades on the Xetra stock exchange.
Is SCHOTT Pharma AG & Co KgaA a Good Stock to Buy?
Determining whether SCHOTT Pharma AG & Co KgaA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1SXP quote. (ISIN: DE000A3ENQ51)
What Is the SCHOTT Pharma AG & Co KgaA Stock Price Today?
The SCHOTT Pharma AG & Co KgaA stock price today is 14.98.
What Is the Stock Symbol for SCHOTT Pharma AG & Co KgaA?
The stock symbol for SCHOTT Pharma AG & Co KgaA is "1SXP."
What Stock Exchange Does SCHOTT Pharma AG & Co KgaA Trade On?
SCHOTT Pharma AG & Co KgaA is listed and trades on the Xetra stock exchange.
Is SCHOTT Pharma AG & Co KgaA a Good Stock to Buy?
Determining whether SCHOTT Pharma AG & Co KgaA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1SXP quote. (ISIN: DE000A3ENQ51)
Currency in EUR
14.98
-0.04(-0.27%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.88
15.12
52 wk Range
14.56
30.25
1SXP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.8815.12
52 wk Range
14.5630.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.20%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.20%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1SXP Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
19.95
Upside
+33.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
- SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - SCHOTT Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
SCHOTT Pharma AG & Co KgaA Company Profile
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
SCHOTT Pharma AG & Co KgaA Earnings Call Summary for Q4/2025
- SCHOTT Pharma reported Q4 2025 revenue of €986 million, up 3% YoY (5.8% at constant currencies), with high-value solutions contributing 57% of total revenues
- EBITDA rose to €280 million with margin improving to 28.4%, though EPS declined slightly to €0.97 from €0.99, triggering a 3.54% stock price drop
- The company proposed a dividend increase to €0.18 per share and announced capital expenditures of €140-€160 million for FY 2026
- FY 2026 guidance projects 2-5% revenue growth at constant currencies with an EBITDA margin of approximately 27%, with executives describing 2026 as a 'bridge year'
- SCHOTT Pharma's exposure to the mRNA market has decreased from 10% to 5%, while the company continues to see growth in GLP-1 therapies
Last Updated: 12/11/2025, 07:18 PM
Read Full TranscriptCompare 1SXP to Peers and Sector
Metrics to compare | 1SXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1SXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 15.4x | 24.9x | −0.6x | |
PEG Ratio | −7.63 | 0.43 | 0.00 | |
Price/Book | 2.5x | 3.0x | 2.6x | |
Price / LTM Sales | 2.3x | 3.1x | 3.4x | |
Upside (Analyst Target) | 35.5% | 20.1% | 41.1% | |
Fair Value Upside | Unlock | 1.8% | 5.3% | Unlock |
Analyst Ratings
6 Buy
5 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 19.95
(+33.18% Upside)
Earnings
Latest Release
Dec 11, 2025
EPS / Forecast
0.2212 / 0.235
Revenue / Forecast
247.61M / 248.32M
People Also Watch
FAQ
What Is the SCHOTT Pharma (1SXP) Stock Price Today?
The SCHOTT Pharma stock price today is 14.98
What Stock Exchange Does SCHOTT Pharma Trade On?
SCHOTT Pharma is listed and trades on the Frankfurt Stock Exchange stock exchange.
What Is the Stock Symbol for SCHOTT Pharma?
The stock symbol for SCHOTT Pharma is "1SXP."
Does SCHOTT Pharma Pay Dividends? What’s The Current Dividend Yield?
The SCHOTT Pharma dividend yield is 1.2%.
What Is the SCHOTT Pharma Market Cap?
As of today, SCHOTT Pharma market cap is 2.26B.
What Is SCHOTT Pharma's Earnings Per Share (TTM)?
The SCHOTT Pharma EPS (TTM) is 0.97.
When Is the Next SCHOTT Pharma Earnings Date?
SCHOTT Pharma will release its next earnings report on Feb 10, 2026.
From a Technical Analysis Perspective, Is 1SXP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has SCHOTT Pharma Stock Split?
SCHOTT Pharma has split 0 times.
How Many Employees Does SCHOTT Pharma Have?
SCHOTT Pharma has 4716 employees.
What is the current trading status of SCHOTT Pharma (1SXP)?
As of Jan 17, 2026, SCHOTT Pharma (1SXP) is trading at a price of 14.98, with a previous close of 15.02. The stock has fluctuated within a day range of 14.88 to 15.12, while its 52-week range spans from 14.56 to 30.25.
What Is SCHOTT Pharma (1SXP) Price Target According to Analysts?
The average 12-month price target for SCHOTT Pharma is EUR19.95, with a high estimate of EUR26 and a low estimate of EUR14. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +33.18% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.